Evidence map›Paper›PMID 38256625›Full record

ArticleJournal of clinical medicine2024

Multimorbidity of Psoriasis: A Large-Scale Population Study of Its Associated Comorbidities.

Manuel Almenara-Blasco, Tamara Gracia-Cazaña, Beatriz Poblador-Plou, Clara Laguna-Berna, Jonás Carmona-Pírez, Alba Navarro-Bielsa, Alexandra Prados-Torres, Antonio Gimeno-Miguel, Yolanda Gilaberte

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  3. Article
  4. Article
  5. Harnessing Quinone Derivatives fromACS pharmacology & translational science · 2025
    Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Manuel Almenara-BlascoDepartment of Dermatology, Miguel Servet University Hospital, IIS Aragon, Paseo Isabel la Católica 1-3, 50009 Zaragoza, Spain.ORCID 0000-0002-4350-401X
Tamara Gracia-CazañaDepartment of Dermatology, Miguel Servet University Hospital, IIS Aragon, Paseo Isabel la Católica 1-3, 50009 Zaragoza, Spain.ORCID 0000-0002-0523-2076
Beatriz Poblador-PlouEpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-5119-5093
Clara Laguna-BernaEpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0009-0007-2903-8159
Jonás Carmona-PírezEpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-6268-8803
Alba Navarro-BielsaDepartment of Dermatology, Miguel Servet University Hospital, IIS Aragon, Paseo Isabel la Católica 1-3, 50009 Zaragoza, Spain.ORCID 0000-0003-1171-6007
Alexandra Prados-TorresEpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-5704-6056
Antonio Gimeno-MiguelEpiChron Research Group, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-5440-1710
Yolanda GilaberteDepartment of Dermatology, Miguel Servet University Hospital, IIS Aragon, Paseo Isabel la Católica 1-3, 50009 Zaragoza, Spain.ORCID 0000-0001-8034-3617
Hospital Universitario Miguel Servet · ESInstituto de Salud Carlos III · ESAndalusian Health Service · ES

Funding

Gobierno de Aragón B01_23RInstituto de Salud Carlos III CM19/00164
6 · The paper itself

Abstract

introductionPsoriasis is a chronic disease of the skin with a prevalence of 2% in the general population. The high prevalence of psoriasis has prompted the study of its comorbidities in recent decades. We designed a study to determine the prevalence of psoriasis in a large-scale, population-based cohort, to exhaustively describe its comorbidities, and to analyze which diseases are associated with psoriasis.

methodsRetrospective, observational study based on the clinical information contained in the electronic health records of the individuals in the EpiChron Cohort with a diagnosis of psoriasis (31,178 individuals) in 2019. We used logistic regression models and calculated the likelihood of the occurrence of each comorbidity based on the presence of psoriasis (

resultsThe prevalence of psoriasis was 2.84%, and it was more prevalent in men (3.31% vs. 2.43%). The most frequent chronic comorbidities were disorders of lipid metabolism (35.87%), hypertension (35.50%), and other nutritional-endocrine-metabolic disorders (21.79%). The conditions most associated with psoriasis were (odds ratio; 95% confidence interval) tuberculosis (2.36; 1.24-4.49), cystic fibrosis (2.15; 1.25-3.69), amongst others. We did not find a significant association between psoriasis and hypertension or neoplasms (0.90; 0.86-0.95).

conclusionsThis study revealed significant associations between psoriasis and cardiac, psychological, and musculoskeletal comorbidities.

Indexed as

comorbiditiesepidemiologypsoriasis

Identifiers

PMID38256625
PMCPMC10816233
OpenAlexW4390913441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.